2,052 Shares in Johnson & Johnson $JNJ Acquired by Redmont Wealth Advisors LLC

Redmont Wealth Advisors LLC purchased a new position in shares of Johnson & Johnson (NYSE:JNJ) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 2,052 shares of the company’s stock, valued at approximately $380,000.

Several other institutional investors and hedge funds have also made changes to their positions in JNJ. Vanguard Group Inc. lifted its holdings in Johnson & Johnson by 1.3% in the second quarter. Vanguard Group Inc. now owns 237,047,859 shares of the company’s stock worth $36,209,060,000 after purchasing an additional 3,085,180 shares during the period. Geode Capital Management LLC increased its holdings in shares of Johnson & Johnson by 2.1% in the second quarter. Geode Capital Management LLC now owns 60,609,476 shares of the company’s stock valued at $9,227,988,000 after buying an additional 1,225,676 shares in the last quarter. Norges Bank purchased a new stake in shares of Johnson & Johnson during the second quarter valued at $4,877,174,000. Bank of New York Mellon Corp boosted its holdings in shares of Johnson & Johnson by 3.5% in the third quarter. Bank of New York Mellon Corp now owns 24,637,649 shares of the company’s stock worth $4,568,313,000 after buying an additional 835,146 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Johnson & Johnson by 0.3% in the second quarter. Charles Schwab Investment Management Inc. now owns 18,951,337 shares of the company’s stock worth $2,894,979,000 after buying an additional 52,074 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Stock Up 0.6%

Shares of Johnson & Johnson stock opened at $244.89 on Thursday. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.03 and a quick ratio of 0.77. The company has a market capitalization of $590.17 billion, a P/E ratio of 22.16, a price-to-earnings-growth ratio of 2.36 and a beta of 0.35. The business has a 50-day moving average of $219.71 and a two-hundred day moving average of $198.21. Johnson & Johnson has a 1 year low of $141.50 and a 1 year high of $246.35.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Saturday, January 31st. The company reported $2.46 earnings per share for the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%.The company had revenue of $24.28 billion during the quarter. As a group, equities analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th will be given a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, February 24th. This represents a $5.20 annualized dividend and a dividend yield of 2.1%. Johnson & Johnson’s dividend payout ratio is presently 47.06%.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, EVP Timothy Schmid sold 22,623 shares of the firm’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $244.33, for a total value of $5,527,477.59. Following the transaction, the executive vice president directly owned 26,769 shares of the company’s stock, valued at $6,540,469.77. This trade represents a 45.80% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Vanessa Broadhurst sold 6,197 shares of the business’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total value of $1,508,287.83. Following the transaction, the executive vice president directly owned 23,003 shares of the company’s stock, valued at approximately $5,598,700.17. The trade was a 21.22% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 0.16% of the company’s stock.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Announced a >$1 billion investment to build a next‑generation cell‑therapy manufacturing facility in Pennsylvania as part of a multi‑year U.S. manufacturing expansion, signaling long‑term capacity growth for its biologics/cell therapy pipeline. Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania
• Positive Sentiment: FDA approved a simplified monthly dosing schedule for RYBREVANT FASPRO (amivantamab + hyaluronidase), improving convenience for EGFR+ NSCLC patients and potentially boosting uptake and product competitiveness. FDA approves RYBREVANT FASPRO as the only EGFR-targeted therapy that can be administered once a month
• Positive Sentiment: Received FDA Breakthrough Therapy Designation for subcutaneous amivantamab (RYBREVANT FASPRO) in advanced head & neck cancer — a regulatory accelerator that can shorten development timelines and enhance commercial prospects if confirmatory data follow. RYBREVANT FASPRO receives U.S. FDA Breakthrough Therapy Designation for head and neck cancer
• Positive Sentiment: Reinforced shareholder returns with a quarterly dividend increase (quarterly payout raised to $1.30), supporting JNJ’s income appeal and dividend‑investor base. Verizon vs Johnson & Johnson: Which Dividend Hike Winner Is the Better Buy?
• Neutral Sentiment: Options activity has picked up interest around JNJ, which can amplify near‑term moves but doesn’t by itself change fundamentals. Watch for large/ directionally concentrated trades. Behind the Scenes of Johnson & Johnson’s Latest Options Trends
• Neutral Sentiment: Street attention and analyst writeups (Zacks, TipRanks) are keeping JNJ in the spotlight; useful for sentiment tracking but incremental to fundamental drivers. Johnson & Johnson (JNJ) Is a Trending Stock
• Neutral Sentiment: A small contract extension with Trellus Health keeps an adherence/support program in place; operationally positive but immaterial to JNJ’s top line. Trellus Health shares double on J&J extension
• Negative Sentiment: Ongoing talc litigation and recent verdict coverage continue to highlight legal risk and valuation uncertainty, which can cap multiple expansion despite operational positives. Johnson And Johnson Talc Verdict Puts Legal Risks And Valuation In Focus

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. BMO Capital Markets reissued an “outperform” rating on shares of Johnson & Johnson in a research note on Thursday, December 11th. Leerink Partners increased their target price on Johnson & Johnson from $201.00 to $232.00 and gave the company a “market perform” rating in a research note on Thursday, January 22nd. The Goldman Sachs Group reiterated a “buy” rating and issued a $250.00 target price on shares of Johnson & Johnson in a research note on Thursday, January 22nd. Wells Fargo & Company boosted their price target on shares of Johnson & Johnson from $230.00 to $240.00 and gave the company an “overweight” rating in a report on Thursday, January 22nd. Finally, Freedom Capital downgraded Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 16th. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $233.73.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.